Abstract:Introduction: Genomic profiling has revolutionized therapeutic interventions and the clinical management of liver cancer. However, pathogenetic mechanisms, molecular determinants of recurrence, and predictive biomarkers for first-line treatment (anti-PD-(L)1 plus bevacizumab) in liver cancer remain incompletely understood. Materials and methods: Targeted next-generation sequencing (tNGS) (a 603-cancer-gene panel) was applied for the genomic profiling of 232 hepatocellular carcinoma (HCC) and 22 intrahepatic cholangiocarcinoma (ICC) patients, among which 47 unresectable/metastatic HCC patients underwent anti-PD-1 plus bevacizumab therapy. Genomic alterations were estimated for their association with vascular invasion (VI), location of onset, recurrence, overall survival (OS), recurrence-free survival (RFS), and anti-PD-1 plus bevacizumab therapy response. Results: The genomic landscape exhibited that the most commonly altered genes in HCC were TP53 , FAT3 , PDE4DIP , KMT2C , FAT1 , and MYO18A , while TP53 , FAT1 , FAT3 , PDE4DIP , ROS1 , and GALNT11 were frequently altered in ICC; notably, KRAS (18.18% vs. 1.29%) and BAP1 (13.64% vs. 1.29%) alterations were significantly more prevalent in ICC. Comparison analysis demonstrated the distinct clinicopathological/genomic characterizations between Chinese and Western HCC cohorts. Genomic profiling of HCC underlying VI showed that LDLR , MSH2 , KDM5D , PDE3A , and FOXO1 were frequently altered in the VI group compared to patients without VIs. Compared to the right hepatic lobes of HCC patients, the left hepatic lobe of HCC patients had superior OS (median OS: 36.77 months vs. unreached, p < 0.05). By further comparison, Notch signaling pathway-related alterations were significantly prevalent among the right hepatic lobes of HCC patients. Of note, multivariate Cox regression analysis showed that altered RB1 , NOTCH3 , MGA , SYNE1 , and ZFHX3 , as independent prognostic factors, were significantly correlated with the OS of HCC patients. Furthermore, altered LATS1 was abundantly enriched in the HCC-recurrent group, and impressively, it was independent of clinicopathological features in predicting RFS (median RFS of altered type vs. wild-type: 5.57 months vs. 22.47 months, p < 0.01). Regarding those treated HCC patients, TMB value, altered PTPRZ1 , and cell cycle-related alterations were identified to be positively associated with the objective response rate (ORR), but KMT2D alterations were negatively correlated with ORR. In addition, altered KMT2D and cell cycle signaling were significantly associated with reduced and increased time to progression-free survival (PFS), respectively. Conclusion: Comprehensive genomic profiling deciphered distinct molecular characterizations underlying VI, location of onset, recurrence, and survival time in liver cancer. The identification of novel genetic predictors of response to anti-PD-1 plus bevacizumab in HCC facilitated the development of an evidence-based approach to therapy.

Recent progress in genomic [corrected] research of liver cancer.

Recent progress in 8igenomic research of liver cancer

Functional Genomic Studies: Insights into the Pathogenesis of Liver Cancer

Whole Genome Sequencing of Matched Tumor, Adjacent Non-Tumor Tissues and Corresponding Normal Blood Samples of Hepatocellular Carcinoma Patients Revealed Dynamic Changes of the Mutations Profiles During Hepatocarcinogenesis.

Genomic Mutations and Molecular Classification of Liver Cancer

Somatic mutations, viral integration and epigenetic modification in the evolution of hepatitis B virus-induced hepatocellular carcinoma.

Abstract LB-309: Comprehensive Genomic Insights into Dynamic Mechanism Underlying the Development of Non-Malignant Human Liver Disease into Hepatocellular Carcinoma

Genome-wide association study: new genetic insights into HBV/HCV-related hepatocellular carcinoma genomes.

Host and Viral Genetic Variation in HBV-Related Hepatocellular Carcinoma

Molecular mechanism of liver cancer.

Hepatitis B 1762T/1764A Mutations, Hepatitis C Infection, and Codon 249 p53 Mutations in Hepatocellular Carcinomas from Thailand

Comparison Study on the Complete Sequence of Hepatitis B Virus Identifies New Mutations in Core Gene Associated with Hepatocellular Carcinoma

Whole-Exome Sequencing-Based Mutational Profiling of Hepatitis B Virus-Related Early-Stage Hepatocellular Carcinoma

Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses

Complete Genome Sequencing and Clinical Analysis of Intrahepatic Hepatitis B Virus Cccdna from HCC.

Diverse Modes of Genomic Alteration in Hepatocellular Carcinoma.

Abstract LB-229: Whole genome sequencing reveals genetic landscape of hepatocellular carcinoma.

Full-length Genomic Analysis of Hepatitis B Virus Isolates in a Patient Progressing from Hepatitis to Hepatocellular Carcinoma.

Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis

Targeted Sequencing of Cancer-Associated Genes in Hepatocellular Carcinoma Using Next Generation Sequencing.

Exome capture sequencing reveals new insights into hepatitis B virus-induced hepatocellular carcinoma at the early stage of tumorigenesis.